Nykode Therapeutics (NYKD) investor relations material

Strategic focus and platform overview

• APC-targeted immunotherapy platform enables precision immune activation for oncology and immune modulation for autoimmune diseases.

• Core focus areas include oncology (Abi-Suva, VB10.NEO) and autoimmune diseases (ASIT platform).

• Proprietary modular design targets antigen-presenting cells (APCs) to train the immune system to attack tumors or restore immune tolerance.

• AI-driven design and screening accelerate candidate selection and improve construct quality across programs.

• Strong financial position with cash runway into 2028–2029, supporting key milestones.

Lead asset: Abi-Suva (VB10.16)

• Off-the-shelf DNA-based immunotherapy targeting HPV16+ cancers, including head & neck, cervical, and other indications.

• Demonstrated strong and durable clinical responses across three trials, with improved ORR and survival versus historical controls.

• Consistent immune activation correlates with clinical outcomes; safe and well tolerated.

• Phase 2 Abili-T trial in 1L HPV16+ r/m HNSCC underway, with first interim analysis expected in 2027.

• Market potential supported by growing HPV16+ cancer incidence and significant unmet need.

VB10.NEO: Individualized Neoantigen Therapy

• Personalized DNA-based cancer vaccine platform with proprietary NeoSELECT AI algorithm for neoantigen selection.

• Two clinical trials show robust immune responses in heavily pre-treated patients across multiple tumor types.

• Demonstrated scalable manufacturing with competitive turnaround time (TAT) and lower cost of goods versus mRNA approaches.

• Durable immune responses observed up to a year post-vaccination.

• Positioned to benefit from upcoming peer readouts in the INT field.